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Abstract
Background: The transmissible spongiform encephalopathies (TSEs) are a group of
neurodegenerative diseases affecting both human and animals. The neuroanatomical changes which
occur in the central nervous system (CNS) of TSE infected animals include vacuolation, gliosis,
neuronal loss and the deposition of a disease specific protein, PrPSc. Experimental murine models
of scrapie, a TSE of sheep, have revealed that pathology may be confined to specific brain areas with
targeting of particular neuronal subsets depending on route of injection and scrapie isolate.
To assess the biochemical changes which are taking place in these targeted areas it was necessary
to develop a reliable sampling procedure (microdissection) which could be used for a variety of
tests such as western blotting and magnetic resonance spectroscopy.
Methods: The method described is for the microdissection of murine brains. To assess the
usefulness of this dissection technique for producing similar sample types for analysis by various
down-stream biochemical techniques, the areas dissected were analysed for PrPSc by western
blotting and compared to immunocytochemical (ICC) techniques.
Results: Results show that the method generates samples yielding a consistent protein content
which can be analysed for PrPSc. The areas in which PrPSc is found by western blotting compares
well with localisation visualised by immunocytochemistry.
Conclusion: The microdisssection method described can be used to generate samples suitable for
a range of biochemical techniques. Using these samples a range of assays can be carried out which
will help to elucidate the molecular and cellular mechanisms underlying TSE pathogenesis. The
method would also be useful for any study requiring the investigation of discrete areas within the
murine brain.
Background
Transmissible spongiform encephalopathies are a group
of neurodegenerative diseases which include scrapie,
bovine spongiform encephalopathy (BSE), and Creut-
zfeldt-Jakob disease (CJD). Murine models have increased
our understanding of the pathogenesis and biochemistry
of scrapie and indeed have been an invaluable tool in the
characterisation of emerging TSEs such as BSE and vCJD
(variant form of CJD linked to BSE exposure)  [1,2].
Scrapie in murine models has a long asymptomatic phase,
the length of which is characteristic of the model, fol-
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death [3]. Neuropathology of a TSE infected animal
reveals vacuolation of the neuropil, gliosis, and neuronal
loss [4,5]. Another major pathological feature of scrapie is
deposition of an abnormal form of the protein PrP [6]
which is also found in the brains of other TSE disease
affected animals [7,8]. PrP is a host-encoded glycoprotein
with a primary structure of approximately 210 amino
acids [9,10]. There are two N-linked glycosylation sites
and a C-terminal glycophosphoinositol (GPI) anchor
[11,12]. The unglycosylated protein has a molecular mass
of about 25 kDa increasing to 33–35 kDa when fully gly-
cosylated. The normal form of the protein is both deter-
gent soluble and protease sensitive [13] in contrast to the
abnormal form which is characterised by its relative pro-
tease resistance and insolubility in detergents. When
treated with proteinase K the abnormal protein is partially
digested and the resulting protease resistant form,
migrates on a 1-dimensional electrophoresis gel (SDS-
PAGE) to a distinct three band pattern with molecular
mass between 18–30 kDa. The relative amounts of these
bands has been examined as a possible diagnostic tool
[14-16]. Glycosylation is also host controlled [17] and the
banding pattern may also be specific to particular brain
areas and neuronal subsets [18].
The murine scrapie models 87V and ME7 used in this
experiment define the variation in pathology found in TSE
pathogenesis. The 87V model displays PrPSc in plaques
and restricted labeling [19]. By contrast in the ME7 model,
PrPSc is found throughout the brain  [20,21]. The variation
in temporal and spatial distribution of PrPSc and the
mechanisms leading to neurodegenerative changes seen
at terminal stages have still to be elucidated. To under-
stand the neurodegenerative events leading to neuronal
loss, we have recognised the need to isolate specific brain
areas and examine each biochemically for mechanisms
such as apoptosis and PrPSc deposition. Whilst other
groups have examined biopsies from specific brain areas
in humans  [22] and by dissection in hamsters [18], we
require a method for murine brains which is reproducible
and can be used in a range of biochemical tests. As only a
small amount of tissue is obtained from a murine brain,
biochemical methods, in particular a western blotting
technique for PrPSc had to be adapted to maximise
sensitivity.
We report our method of collection of samples and show
immunoblots of PrPSc deposition within microdissected
areas, as an illustration of use within the TSE field. The
method however could be used to collect samples from
murine models in other areas of research.
Methods
Animals
All animals used in the experiment were housed and pro-
cedures carried out within a UK Home Office licensed unit
which complies with the Animals (Scientific Procedures)
Act 1986. Two inbred mouse strains VM/Dk Prnb (VM)
and VM/Dk Prna(SV) were inoculated intracerebrally with
20µl of a 1% (w/v) brain suspension of either 87V (VM)
or ME7 (SV) strains of scrapie. Similar control groups were
inoculated with a normal brain homogenate. The animals
were culled by cervical dislocation at suitable intervals
throughout disease, (ME7 model: every 30 days post
injection (dpi) until the terminal stage of disease at about
160 dpi. 87V model: every 50 dpi until about 300 dpi).
The brain was removed and carefully placed (to avoid
damage during freezing) in a plastic universal tube, flash
frozen in liquid nitrogen, and stored at -70°C. Brain sam-
ples for histology were fixed in 10% formol saline (see
section 2.4).
Three brains were collected at each time point and micro-
dissected for Western blotting as described in the follow-
ing sections. Weights from samples obtained by
microdissection are shown in Table 1.
Microdissection
Microcentrifuge tubes numbered with animal number
and brain area were weighed on a fine balance (Stanton).
A cold plate (Model E/66.3 Raymond Lamb Laboratory
Supplies) was set to -10°C, and covered with aluminium
foil for each sample. The brain was allowed to partially
thaw before placing on the cold plate area.
Table 1: Table showing the mean weights of dissected brain areas.
Brain Area No. of brains dissected Mean Weight (mg) SD SEM
Cerebellum 118 22.2 5.06 0.47
Brain Stem 118 32.4 9.38 0.86
Dorsal Raphe * 118 4.2 1.15 0.11
Hippocampus * 118 6.2 1.29 0.12
Cortex 118 15.1 3.18 0.29
Thalamus 118 21.1 5.10 0.47
Paraterminal Body * 118 4.3 1.27 0.12
*areas taken using punch techniquePage 2 of 9
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scalpel (Swann Norton No.11) four slices were coronally
cut as in Fig. 1. Each slice was further dissected by cutting
out areas of interest as shown in Fig. 2. Where the area of
interest was too small for accurate dissection in this man-
ner, a punch method was employed.
Using the cannula only of a biopsy needle (Seldinger nee-
dle, 18 g, 7 cms, Scottish Medical) a "core" of selected
brain area was sampled by punching through the brain
slice. Four to six punches were sampled and expelled by
use of a syringe attached to the end of the cannula into the
weighed microcentrifuge tube (Fig. 3). All samples after
microdissection were immersed in liquid nitrogen imme-
diately. The microcentrifuge tube was then re-weighed,
the weight noted and the sample stored at -70°C.
Every effort is made in the method to avoid tissue degra-
dation. The whole brain was flash frozen and microdissec-
tion carried out on a cold plate. After microdissection the
tubes containing microdissected areas are again flash fro-
zen to avoid any loss of protein. As continual freezing and
thawing would degrade the protein the samples had to be
weighed between coming out of the liquid nitrogen and
storing in the freezer without further thawing. In order to
allow for discrepancies in weight due to freezing effects,
two empty microtubes were weighed before and re-
weighed after immersion in liquid nitrogen. The differ-
ence between the weights (average 0.0020 g) is used as a
correction factor and subtracted from the sample tubes. In




Each sample was homogenized in 10% wt/vol. lysis buffer
(100 mM Tris buffered saline (TBS) pH 7.5, 0.5% deoxy-
cholic acid, 0.5% NP40) using a battery operated homog-
eniser (Sigma Aldrich) with disposable pellet mixer
(Anachem) attached.
The homogenate was then halved, proteinase K (final con-
centration 20 µg/ml) added to one aliquot (+PK) and
digested at 37°C in a water bath for 40 minutes. To stop
further degradation due to protease digestion a solution
of 100 mM phenylmethanesulfonyl fluoride (PMSF), 100
mM N-ethylmaleimide (NEM) in propan-2-ol to a final
concentration of 10 mM was added. The protease inhibi-
tors were also added to the untreated (-PK) aliquot.
Protein precipitation was then carried out using 4 × vol. of
an ice-cold mixture of 2% acetic acid in methanol. After
freezing overnight at -20°C the samples were centrifuged
for 10 minutes at 16,000 g, the supernatant removed and
the pellet dried for one hour in a centrifugal vacuum con-
centrator (Thermo Savant Speed-Vac).
Protein estimation
Total protein estimation was carried out following the
microwell plate protocol of a BCA Protein Assay Kit avail-
able from Perbio Science(Product 23225 & 23227). A 5 µl
aliquot of homogenate was pipetted to a microtitre plate
well containing 20 µl of distilled water i.e.1:5 dilution of
original homogenate. A range of standards were prepared
as per the protocol, using similarly diluted lysis buffer as
diluent. The samples and standards were read and ana-
lysed on a 'Molecular Devices' v-max microplate reader.
The protein content of seven brains, taken at different
time points throughout disease progression, are shown in
Table 2.
Electrophoresis
The pellet was solubilised in 1 × sample buffer (dilution
of 5 × sample buffer (Tris-HCl, 60 mM pH 6.8, 25%
glycerol, 2% sodium dodecyl sulfate (SDS), 1% 2-mercap-
toethanol, deionised water), to give a concentration of
10% the original tissue weight per volume. The sample
was briefly vortexed, heated for 15 minutes at 98°C,
briefly vortexed again and centrifuged at 16000 g for 5
mins. A 10 µl aliquot of the sample was then electro-
phoresed in a 12% SDS-PAGE mini gel. A protein
standard was also loaded and the gel was run until the dye
front reached the bottom of the gel.
Gel systems
The use of mini gel systems was not as universally used as
they are at present when this work was initiated therefore
Coronally cut sectionsFigure 1
Coronally cut sections Approximate levels as detailed in 
Sidman et al [24] 1 – Fig. 74 – Coronal section 455 2 – Fig. 64 
– Coronal section 413 3 – Fig. 46 – Coronal section 321 4 – 
Fig. 25 – Coronal section 180
214 3Page 3 of 9
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Bio-Rad Mini Protean II system with a 12% Tris/HCl ready
gel (using SDS buffers) was used to electrophorese the
ME7 samples. A BioRad LW Kaleidoscope prestained pro-
tein standard was used to estimate molecular weight. The
Invitrogen, NuPAGE® gel system with 12%Tris-Glycine gel
and SDS buffers was used to electrophorese the 87V sam-
ples with a MultiMark® multi coloured prestained protein
standard.
Immunoblotting
The gel was then blotted (BioRad Semi-dry Blotter or
Novex blotting system) onto a PVDF membrane (Immo-
bilon – P, Millipore). On unloading, the membrane was
placed in methanol for 10 seconds, rinsed in TBS, fol-
lowed by 0.5% blocking solution (western blocking rea-
gent, Roche) for 5 minutes. The blot was incubated
overnight with 6H4 monoclonal antibody (Prionics AG)
made up in blocking solution at a concentration of
1:30,000. The primary antibody was drained and the blot
rinsed once with TBST (0.1% Tween in TBS), followed by
a further rinse in blocking solution. The secondary anti-
body (Jackson Immunoresearch Laboratories POD conju-
gated Affinity pure donkey anti-mouse IgG (H+L)) was
applied in blocking solution at a 1:30,000 concentration
and incubated for 90 minutes. The blots were washed four
times with TBST before using the visualization kit. All
washes and incubations were carried out using an orbital
shaker.
Visualization
Visualization was achieved by using a western blotting kit
(Pierce West Dura Western Blotting Kit) according to
manufacturers' instructions. The blot was enclosed in a
plastic covering, and placed in a cassette with photo-
graphic film at exposures of 30 seconds, 1 and 2 minutes.
Photographic film was used in preference to a densitome-
Maps of dissected areasFigure 2








A - Cerebellum 
B - Brain Stem  
C - Dorsal raphe 
D - Hippocampus 
E - Cortex
F - Thalamus
G -Paraterminal  bodyPage 4 of 9
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ise as much PrPSc as possible. Examples of the
immunoblots for both ME7 and 87V can be seen in Figure
4.
Immunocytochemistry
Immunocytochemistry was carried out as described in
Brown et al [23]. Briefly brains were fixed in 10% formol
saline and embedded in paraffin wax. Coronal sections (6
µm) were pretreated using hydrated autoclaving for 15
minutes at 121°C and immersed in 98% formic acid for
10 minutes. PrP was immunolabelled by incubation over-
night with 6H4 (Prionics) as primary antibody at a 1:1000
dilution. A biotinylated rabbit anti-mouse (Jackson
ImmunoResearch Laboratories) secondary antibody was
applied and the slide incubated for 1 hour. The ABC Elite
kit (Vector Laboratories) was used throughout and visual-
ization was achieved using 3,3' diaminobenzidine
(Merck).
Results
Evaluation of microdissection technique
Despite a small size of sample produced by microdissec-
tion, the weights of brain areas were reproducible over a
large number of samples (see Table 1). In contrast with
the weights of samples taken by dissection, such as cere-
bellum, brain stem and thalamus the samples taken with
biopsy needle i.e. hippocampus, dorsal raphe and
paraterminal body show little variation in weight indicat-
ing that this is a particularly precise way of sampling the
brain area of interest. The protein content (see standard
deviations in Table 2) was very consistent in the samples
indicating that the method is useful for further compara-
tive protein analysis.
PrPSc detection
PrPSc was detected in all samples as demonstrated in the
immunoblots shown in Figure 4. In the samples without
proteinase K digestion a series of bands can be seen at a
Punch TechniqueFigure 3
Punch Technique A – needle punching B – expelling sample from needle
Table 2: %Protein Content in samples
Brain Area No. of brains dissected % protein in sample SD SEM
Cerebellum 7 1.79 0.50 0.19
Brain Stem 7 1.30 0.47 0.18
Dorsal Raphe 7 1.41 0.51 0.19
Hippocampus 7 1.25 0.27 0.10
Cortex 7 1.65 0.31 0.12
Thalamus 7 1.69 0.23 0.09
Paraterminal Body 7 2.10 0.94 0.35
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Diagram of microdissected areas with corresponding PrPSc immunolabelled sections and immunoblots taken 
at different time points throughout disease. Sections and immunoblots numbered; (1–3) -87V scrapie model; (4–5) -ME7 
scrapie model; immunoblots show both PK treated (+) and untreated samples (-) normal brain (NB), numbers(at the foot of 
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PrP content, i.e. a mixture of PrPc and PrPSc before and
after proteolytic cleavage. In Tables 3 &4 a scoring system
denotes the presence of PrPSc. A (+) sign signifies where
PrPSc was visible in the immunoblots of at least two out of
the three microdissected brains. A (?) denotes where PrPSc
was visible in one blot but not in the other two.
The distribution of PrPSc throughout areas of the brain in
the 87V model (Table 3) is strikingly different to that of
the ME7 model (Table 4). In the 87V model only the brain
stem and dorsal raphe are positive at 50% of the
incubation period (150 dpi) By comparison every area
except the cerebellum was positive at the same percentage
incubation period of the ME7 model (90 dpi). The first
clinical signs in the 87V model are around 93% of the
incubation period (272 dpi), by which time all the brain
areas, in contrast with the previous time point (240 dpi)
show PrPSc deposition. Western blotting has failed to
show PrPSc in the cerebellum and definitively in the cortex
of this model, perhaps due to sparse plaque distribution
in these areas suggesting a low concentration. PrPSc depo-
sition in ME7 model begins very early in the incubation
period (60 dpi) appearing within the hippocampus cor-
tex, thalamus and paraterminal body. Again the immuno-
blot is only positive in the hippocampus at this time
point. In contrast with the 87V model, all areas have PrPSc
deposition at 75% of incubation (120 dpi). The first
clinical signs in this model are around 92% of incubation
(151 dpi) which is a similar percentage to the 87V model.
Discussion
The microdissection technique described above provides
a method for obtaining samples from targeted areas to be
examined biochemically. The sensitivity of the immunob-
lotting technique has been optimised to allow for smaller
weights of sample to be tested for PrPSc. Combining the
two methods provides a tool with which to examine pro-
gression of disease within defined areas, thereby supple-
menting information gained through histopathological
Table 3: Deposition of PrPSc in microdissected areas of 87V scrapie model.
DPI A B C D E F G





150 + ? +
180 + N/A + N/A N/A
210 + + + + N/A
240 + + + + + + ? + + + ? +
270 + + + + + + + ? + + + + +
300 All -ve + + + + + + + ? + + + + +
Comparison of dissected brain areas (A-G as in Fig. 2) throughout time course of disease (dpi) in 87V scrapie model. PrPSc deposition (+) visualised 
by immunocytochemistry (I) and western blotting(W) using 6H4Mab, (?) denotes where PrPSc was visualised in one brain only(see section 2.4), 
section not available (N/A).
Table 4: Deposition of PrPSc in microdissected areas of ME7 scrapie model
DPI A B C D E F G
W I W I W I W I W I W I W I
30
60 + + + + +
90 ? + + + + ? + + + + +
120 + N/A ? + + + + + + + + + + +
150 + N/A + + + + + + + + + + + +
EP + N/A + + + + + + + + + + + +
Comparison of dissected brain areas (A-G as in Fig. 2) throughout time course of disease (dpi) in ME7 scrapie model. PrPSc deposition (+) visualized 
by immunocytochemistry (I) and western blotting (W)using 6H4Mab, (?) denotes where PrPSc was visualized in one brain only(see section 2.4), (N/
A) section not available.Page 7 of 9
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film for detecting PrPSc however to estimate glycosylation
ratios in each brain area densitometry could be carried
out. Our immunocytochemical findings agree with a
previous study by Bruce et al [19] in which these models
were also compared using a different antibody and a more
limited serial kill.
It is interesting to note that although the 87V model has
more targeted PrPSc deposition and the amount present
overall is less than the ME7 model, both have similar time
points where clinical signs are apparent. As has been
observed in other models [23], the concentration of PrPSc
within the brain as a whole does not dictate the fate of the
animal. PrPSc may be in a particular neurotoxic form to
which critical areas of the brain succumb leading to the
eventual death of the animal. By isolating particular brain
areas with methods such as the microdissection described
we may examine other events leading to neurodegenera-
tion in the TSEs which may elucidate the role of PrP.
Conclusions
The microdissection protocol provides a standardized
approach to obtaining samples from brain areas for
analysis. The method described allows us to isolate partic-
ular brain areas to examine the events leading to neurode-
generation in the TSE group of diseases. We have already
used this method to isolate areas for analysis by magnetic
resonance spectroscopy (manuscript in preparation) and
for a proteomics study (in progress). In this paper we have
demonstrated that PrPSc distribution throughout the brain
displayed by immunocytochemistry techniques, can be
definitively verified by western blotting the microdis-
sected areas. Using the microdissection of discrete brain
areas in combination with other analytical methods will
provide a qualitative and quantitative approach in assess-
ing the pathogenesis of TSE infection. The microdissec-
tion method could also prove useful in other areas of
research where the isolation of discrete murine brain areas
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